IMNM Q3 2025 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$49M

Operating Income

-$60M

Net Income

-$57M

EPS (Diluted)

$-0.65

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$42M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$299M

Total Liabilities

$35M

Stockholders' Equity

$264M

Cash & Equivalents

$273M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$3M	-100.0%
Gross Profit	-$49M	$3M	-1790.5%
Operating Income	-$60M	-$51M	-19.0%
Net Income	-$57M	-$47M	-22.0%